Last reviewed · How we verify

NCT03721055

Fluoroglutamine PET/CT in Imaging Patients With Malignant Tumor

Status unknown NA Last updated 6 September 2019
What this trial tests

NA trial testing 18F-(2S,4R)4-fluoroglutamine in Cancer in 60 participants. Status unknown.

Timeline
21 August 2017
Primary endpoint
31 December 2019
31 December 2019

Quick facts

Lead sponsorXinhua Hospital, Shanghai Jiao Tong University School of Medicine
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment60
Start date21 August 2017
Primary completion31 December 2019
Estimated completion31 December 2019
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

Adults 18 to 79, any sex, with Cancer or Metastatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial studies positron emission tomography (PET) imaging utilizing 18F-(2S,4R)4-fluoroglutamine, a glutamic acid derivative, to image patients with malignant tumor. \[18F\]Fluoroglutamine PET may provide additional information that help diagnose and stage cancer patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of 18F-(2S,4R)4-fluoroglutamine

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03721055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing